LUCD (Lucid Diagnostics, Inc) Rentabilitas dodolan reged

Simbol resmi perusahaan Lucid Diagnostics, Inc. (LUCD)

Lucid Diagnostics Inc. (LUCD) maintains its leadership status in the early detection of esophageal cancer thanks to the precise EsoGuard test. The gross margin history on the GURU.Markets chart shows that the indicator settled at -32.70. Profit growth relies on insurance coverage and physician recognition, while stability is ensured by a streamlined express delivery of biomaterials to the central laboratory complex.

LUCD (Lucid Diagnostics, Inc.) riwayat Margin reged saka 04.07.2022 nganti 19.11.2026

Rincian metrik keuangan lan pasar Lucid Diagnostics, Inc (LUCD)

- kuotasi saiki lan rata-rata prakiraan nilai:
Pambiji fundamental:LUCD (Lucid Diagnostics, Inc.)
Produk seri Lucid Diagnostics Inc

Gross margin measures production efficiency by determining the profit share after deducting direct costs, allowing investors to assess the pricing power and operational resilience of the business. For Lucid Diagnostics Inc. (LUCD), the implementation of robotic biosample analysis systems reduces manual labor costs, and the gross margin level reflects the degree of optimization of these technological processes.